Authorized purpose: CADx assistance for assessment and characterization of brain tissue abnormalities and early ischemic injury in patients with known MCA or ICA occlusion, using ASPECTS regions and scoring to evaluate extent of disease during image interpretation.
Clinical role
Post-acquisition NCCT preprocessing, tilt correction, predefined-ROI analysis, and automatic ASPECTS scoring; the clinician confirms the occlusion prerequisite, reviews and edits the result, and archives the final output.
Images and patients
CT/CTA · Brain, including ASPECTS regions
Key limitation
Keep in mind: Not intended for primary CT interpretation. It is validated and intended for known unilateral MCA or ICA occlusion, brain ischemia within 12 hours from last known well, patients over 21, and the listed Canon, GE, Philips, and Siemens scanner families. It is not suitable for tumors, abscesses, traumatic brain injury, hemorrhagic transformation, or hematoma; excessive motion, streak artifact, or significant noise can make scans technically inadequate.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: CADx assistance for assessment and characterization of brain tissue abnormalities and early ischemic injury in patients with known MCA or ICA occlusion, using ASPECTS regions and scoring to evaluate extent of disease during image interpretation.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain, including ASPECTS regions Input: Non-contrast head CT images in DICOM-compatible clinical imaging workflow from patients over 21 with known unilateral MCA or ICA occlusion, within 12 hours from time last known well, acquired on Canon, GE, Philips, or Siemens scanners; the clinician must confirm the LVO condition before results are available.
Who uses it?Intended users: Neuroradiologists and clinicians, including stroke neurologists, general radiologists, neurointensivists, and vascular neurologists.
What does the software produce?Output: An automatic ASPECTS score reflecting the number of affected regions, delineated and highlighted ASPECTS ROIs, a heat map of contributing voxels, region labels, underlying voxel values, and DICOM output for PACS or workstation review; the clinician can adjust the score.
What is its most important limitation?Key limitation: Not intended for primary CT interpretation. It is validated and intended for known unilateral MCA or ICA occlusion, brain ischemia within 12 hours from last known well, patients over 21, and the listed Canon, GE, Philips, and Siemens scanner families. It is not suitable for tumors, abscesses, traumatic brain injury, hemorrhagic transformation, or hematoma; excessive motion, streak artifact, or significant noise can make scans technically inadequate.
Clinical takeaway. Clinical role: CADx assistance for assessment and characterization of brain tissue abnormalities and early ischemic injury in patients with known MCA or ICA occlusion, using ASPECTS regions and scoring to evaluate extent of disease during image interpretation.
Evidence takeaway. Evidence from the reviewed source record: FDA standalone testing used a retrospective, multicenter, multinational, multi-vendor, blinded study of CINA-ASPECTS v1.5 with 200 anonymized NCCT cases from five sites in the US and France, four scanner makers, and 27 models; the dataset was separated from training/testing data. The MRMC study used eight readers, four expert neuroradiologists and four non-experts, each scoring 10 regions in the 200 cases. Readers agreed with almost one-half region more per scan with the device, 4.1% (95% CI 3.3%-4.9%); overall reader ROC AUC improved from 0.75 unaided to 0.79 aided, and mean time per case decreased. These are reader agreement, reader ROC, and workflow-time endpoints, not device sensitivity or specificity.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
CADx assistance for assessment and characterization of brain tissue abnormalities and early ischemic injury in patients with known MCA or ICA occlusion, using ASPECTS regions and scoring to evaluate extent of disease during image interpretation.
Post-acquisition NCCT preprocessing, tilt correction, predefined-ROI analysis, and automatic ASPECTS scoring; the clinician confirms the occlusion prerequisite, reviews and edits the result, and archives the final output.
Non-contrast head CT images in DICOM-compatible clinical imaging workflow from patients over 21 with known unilateral MCA or ICA occlusion, within 12 hours from time last known well, acquired on Canon, GE, Philips, or Siemens scanners; the clinician must confirm the LVO condition before results are available.
An automatic ASPECTS score reflecting the number of affected regions, delineated and highlighted ASPECTS ROIs, a heat map of contributing voxels, region labels, underlying voxel values, and DICOM output for PACS or workstation review; the clinician can adjust the score.
Not intended for primary CT interpretation. It is validated and intended for known unilateral MCA or ICA occlusion, brain ischemia within 12 hours from last known well, patients over 21, and the listed Canon, GE, Philips, and Siemens scanner families. It is not suitable for tumors, abscesses, traumatic brain injury, hemorrhagic transformation, or hematoma; excessive motion, streak artifact, or significant noise can make scans technically inadequate.
FDA standalone testing used a retrospective, multicenter, multinational, multi-vendor, blinded study of CINA-ASPECTS v1.5 with 200 anonymized NCCT cases from five sites in the US and France, four scanner makers, and 27 models; the dataset was separated from training/testing data. The MRMC study used eight readers, four expert neuroradiologists and four non-experts, each scoring 10 regions in the 200 cases. Readers agreed with almost one-half region more per scan with the device, 4.1% (95% CI 3.3%-4.9%); overall reader ROC AUC improved from 0.75 unaided to 0.79 aided, and mean time per case decreased. These are reader agreement, reader ROC, and workflow-time endpoints, not device sensitivity or specificity.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA standalone testing used a retrospective, multicenter, multinational, multi-vendor, blinded study of CINA-ASPECTS v1.5 with 200 anonymized NCCT cases from five sites in the US and France, four scanner makers, and 27 models; the dataset was separated from training/testing data. The MRMC study used eight readers, four expert neuroradiologists and four non-experts, each scoring 10 regions in the 200 cases. Readers agreed with almost one-half region more per scan with the device, 4.1% (95% CI 3.3%-4.9%); overall reader ROC AUC improved from 0.75 unaided to 0.79 aided, and mean time per case decreased. These are reader agreement, reader ROC, and workflow-time endpoints, not device sensitivity or specificity.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
CINA-ASPECTS regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K233342
Samplen=200
Sites5
IndependenceIndependence not established
K233342
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233342. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Non-contrast head CT images in DICOM-compatible clinical imaging workflow from patients over 21 with known unilateral MCA or ICA occlusion, within 12 hours from time last known well, acquired on Canon, GE, Philips, or Siemens scanners; the clinician must confirm the LVO condition before results are available.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: A standalone executable can run from the command line or through medical image communications devices; it does not interface directly with CT scanners or data-collection equipment. Results are stored in DICOM for transfer to PACS or a workstation, with exact interface versions and local compatibility not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes CINA-ASPECTS as a standalone executable program that may be run directly from the command line or through integration, deployment and use with medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "CINA-ASPECTS is a standalone executable program that may be run directly from the command-" … "line or through integration, deployment and use with medical image communications devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: An automatic ASPECTS score reflecting the number of affected regions, delineated and highlighted ASPECTS ROIs, a heat map of contributing voxels, region labels, underlying voxel values, and DICOM output for PACS or workstation review; the clinician can adjust the score.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: An automatic ASPECTS score reflecting the number of affected regions, delineated and highlighted ASPECTS ROIs, a heat map of contributing voxels, region labels, underlying voxel values, and DICOM output for PACS or workstation review; the clinician can adjust the score.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes CINA-ASPECTS as a standalone executable program that may be run directly from the command line or through integration, deployment and use with medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "CINA-ASPECTS is a standalone executable program that may be run directly from the command-" … "line or through integration, deployment and use with medical image communications devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
A standalone executable can run from the command line or through medical image communications devices; it does not interface directly with CT scanners or data-collection equipment. Results are stored in DICOM for transfer to PACS or a workstation, with exact interface versions and local compatibility not established.
Avicenna.AI's cybersecurity page states ISO/IEC 27001 certification by SGS, IEC 81001-5-1, TLS 1.2+ in transit, encryption at rest, role-based access with least privilege, and a HIPAA business associate agreement for US customers. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for CINA-ASPECTS; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
10Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K233342 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support
Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Authorized purpose: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.
Authorized purpose: Photonova Spectra and Spectra Select are silicon-based spectral photon-counting detector CT systems that acquire cross-sectional body images, multienergy data, monochromatic images, and material-density maps for labeled head, whole-body, cardiac, vascular, and lung workflows.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.